145 related articles for article (PubMed ID: 29688337)
1. Stimulation of S1PR5 with A-971432, a selective agonist, preserves blood-brain barrier integrity and exerts therapeutic effect in an animal model of Huntington's disease.
Di Pardo A; Castaldo S; Amico E; Pepe G; Marracino F; Capocci L; Giovannelli A; Madonna M; van Bergeijk J; Buttari F; van der Kam E; Maglione V
Hum Mol Genet; 2018 Jul; 27(14):2490-2501. PubMed ID: 29688337
[TBL] [Abstract][Full Text] [Related]
2. Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease.
Fatoba O; Kloster E; Reick C; Saft C; Gold R; Epplen JT; Arning L; Ellrichmann G
Exp Neurol; 2018 Apr; 302():112-128. PubMed ID: 29309751
[TBL] [Abstract][Full Text] [Related]
3. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain.
Ginés S; Bosch M; Marco S; Gavaldà N; Díaz-Hernández M; Lucas JJ; Canals JM; Alberch J
Eur J Neurosci; 2006 Feb; 23(3):649-58. PubMed ID: 16487146
[TBL] [Abstract][Full Text] [Related]
4. Expression of brain-derived neurotrophic factor in astrocytes - Beneficial effects of glatiramer acetate in the R6/2 and YAC128 mouse models of Huntington's disease.
Reick C; Ellrichmann G; Tsai T; Lee DH; Wiese S; Gold R; Saft C; Linker RA
Exp Neurol; 2016 Nov; 285(Pt A):12-23. PubMed ID: 27587303
[TBL] [Abstract][Full Text] [Related]
5. Topoisomerase 1 inhibitor topotecan delays the disease progression in a mouse model of Huntington's disease.
Shekhar S; Vatsa N; Kumar V; Singh BK; Jamal I; Sharma A; Jana NR
Hum Mol Genet; 2017 Jan; 26(2):420-429. PubMed ID: 28007908
[TBL] [Abstract][Full Text] [Related]
6. Wheel running and environmental enrichment differentially modify exon-specific BDNF expression in the hippocampus of wild-type and pre-motor symptomatic male and female Huntington's disease mice.
Zajac MS; Pang TY; Wong N; Weinrich B; Leang LS; Craig JM; Saffery R; Hannan AJ
Hippocampus; 2010 May; 20(5):621-36. PubMed ID: 19499586
[TBL] [Abstract][Full Text] [Related]
7. The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington's disease.
Doria JG; de Souza JM; Andrade JN; Rodrigues HA; Guimaraes IM; Carvalho TG; Guatimosim C; Dobransky T; Ribeiro FM
Neurobiol Dis; 2015 Jan; 73():163-73. PubMed ID: 25160573
[TBL] [Abstract][Full Text] [Related]
8. Treatment with a herbal formula B401 enhances neuroprotection and angiogenesis in the R6/2 mouse model of Huntington's disease.
Wang SE; Lin CL; Hsu CH; Sheu SJ; Chien CT; Wu CH
Drug Des Devel Ther; 2015; 9():887-900. PubMed ID: 25733809
[TBL] [Abstract][Full Text] [Related]
9. Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease.
Ferrante A; Martire A; Pepponi R; Varani K; Vincenzi F; Ferraro L; Beggiato S; Tebano MT; Popoli P
Neurobiol Dis; 2014 Nov; 71():193-204. PubMed ID: 25132555
[TBL] [Abstract][Full Text] [Related]
10. Nucleic Acid Therapeutics in Huntington's Disease.
Singh K; Roy I
Recent Pat Biotechnol; 2019; 13(3):187-206. PubMed ID: 30747088
[TBL] [Abstract][Full Text] [Related]
11. Early white matter abnormalities, progressive brain pathology and motor deficits in a novel knock-in mouse model of Huntington's disease.
Jin J; Peng Q; Hou Z; Jiang M; Wang X; Langseth AJ; Tao M; Barker PB; Mori S; Bergles DE; Ross CA; Detloff PJ; Zhang J; Duan W
Hum Mol Genet; 2015 May; 24(9):2508-27. PubMed ID: 25609071
[TBL] [Abstract][Full Text] [Related]
12. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model.
Peng Q; Masuda N; Jiang M; Li Q; Zhao M; Ross CA; Duan W
Exp Neurol; 2008 Mar; 210(1):154-63. PubMed ID: 18096160
[TBL] [Abstract][Full Text] [Related]
13. Treatment with THI, an inhibitor of sphingosine-1-phosphate lyase, modulates glycosphingolipid metabolism and results therapeutically effective in experimental models of Huntington's disease.
Pepe G; Capocci L; Marracino F; Realini N; Lenzi P; Martinello K; Bovier TF; Bichell TJ; Scarselli P; Di Cicco C; Bowman AB; Digilio FA; Fucile S; Fornai F; Armirotti A; Parlato R; Di Pardo A; Maglione V
Mol Ther; 2023 Jan; 31(1):282-299. PubMed ID: 36116006
[TBL] [Abstract][Full Text] [Related]
14. Improvement of BDNF signalling by P42 peptide in Huntington's disease.
Couly S; Paucard A; Bonneaud N; Maurice T; Benigno L; Jourdan C; Cohen-Solal C; Vignes M; Maschat F
Hum Mol Genet; 2018 Sep; 27(17):3012-3028. PubMed ID: 29860423
[TBL] [Abstract][Full Text] [Related]
15. Stimulation of Sphingosine Kinase 1 (SPHK1) Is Beneficial in a Huntington's Disease Pre-clinical Model.
Di Pardo A; Pepe G; Castaldo S; Marracino F; Capocci L; Amico E; Madonna M; Giova S; Jeong SK; Park BM; Park BD; Maglione V
Front Mol Neurosci; 2019; 12():100. PubMed ID: 31068790
[TBL] [Abstract][Full Text] [Related]
16. Multidrug resistance protein 1 reduces the aggregation of mutant huntingtin in neuronal cells derived from the Huntington's disease R6/2 model.
Im W; Ban JJ; Chung JY; Lee ST; Chu K; Kim M
Sci Rep; 2015 Nov; 5():16887. PubMed ID: 26586297
[TBL] [Abstract][Full Text] [Related]
17. Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347.
Conforti P; Ramos C; Apostol BL; Simmons DA; Nguyen HP; Riess O; Thompson LM; Zuccato C; Cattaneo E
Mol Cell Neurosci; 2008 Sep; 39(1):1-7. PubMed ID: 18571429
[TBL] [Abstract][Full Text] [Related]
18. Cerebrovascular and blood-brain barrier impairments in Huntington's disease: Potential implications for its pathophysiology.
Drouin-Ouellet J; Sawiak SJ; Cisbani G; Lagacé M; Kuan WL; Saint-Pierre M; Dury RJ; Alata W; St-Amour I; Mason SL; Calon F; Lacroix S; Gowland PA; Francis ST; Barker RA; Cicchetti F
Ann Neurol; 2015 Aug; 78(2):160-77. PubMed ID: 25866151
[TBL] [Abstract][Full Text] [Related]
19. p35 hemizygosity activates Akt but does not improve motor function in the YAC128 mouse model of Huntington's disease.
Park KHJ; Franciosi S; Parrant K; Lu G; Leavitt BR
Neuroscience; 2017 Jun; 352():79-87. PubMed ID: 28391013
[TBL] [Abstract][Full Text] [Related]
20. BH3-only proteins Bid and Bim(EL) are differentially involved in neuronal dysfunction in mouse models of Huntington's disease.
García-Martínez JM; Pérez-Navarro E; Xifró X; Canals JM; Díaz-Hernández M; Trioulier Y; Brouillet E; Lucas JJ; Alberch J
J Neurosci Res; 2007 Sep; 85(12):2756-69. PubMed ID: 17387706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
